Scientists Identified Antibodies for Alpha-Gal Syndrome

Researchers discovered antibodies that may block allergic reactions linked to tick bites in a September 2026 study.

Updated on Sept. 23, 2026 in Allergies

A close-up of a pipette dispensing a clear liquid into a small, clean glass vial in a bright, modern laboratory setting. — Researchers at the University of North Carolina at Chapel Hill identified monoclonal antibodies that may block allergic reactions linked to alpha-gal syndrome. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical research will significantly improve treatment options for chronic allergies?

A study published September 1, 2026, in the Journal of Clinical Investigation revealed that researchers identified monoclonal antibodies capable of binding to alpha-gal allergens. This breakthrough offers a potential new path for treating the tick-borne condition.

Why it matters

Alpha-gal syndrome, which triggers allergic reactions to a sugar molecule, currently lacks targeted medical interventions. The findings provide a foundation for developing treatments to prevent these immune responses in affected patients.

Researchers created 42 monoclonal antibodies, with 13 binding to alpha-gal allergens and two successfully blocking IgE attachment. The team also observed that one antibody interfered with the activation of basophils.

The players

University of North Carolina at Chapel Hill

This public research university served as the site for the lead research team investigating alpha-gal syndrome treatments.

Journal of Clinical Investigation

This peer-reviewed medical publication disseminated the research findings on monoclonal antibodies in September 2026.

The details

The research team at the University of North Carolina at Chapel Hill screened 42 monoclonal antibodies originally intended for malaria research to test for reactivity with alpha-gal. They specifically analyzed whether these candidates could prevent IgE from patients with the syndrome from binding to allergens.

Since 2010, the U.S. has seen 110,000 suspected cases of the condition.
The findings were published on September 1, 2026.

The Big Picture

The study advances the broader application of monoclonal antibody therapies into the field of tick-borne allergy management. By repurposing antibodies initially developed for malaria research, the work follows a pattern of cross-disciplinary innovation in immunology.

These findings do not yet provide an immediate clinical treatment for those living with the syndrome. Patients should continue to manage their condition by avoiding bites from certain ticks and adhering to current medical guidance.

The takeaway

Future studies will investigate if these specific antibodies can prevent allergic reactions in individuals with alpha-gal syndrome. Researchers are also exploring strategies to expand this approach to target a wider array of alpha-gal allergens.